EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 679 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR No OS Benefit for Active Maintenance Treatment with Olaparib Relative to... July 22, 2022 Neoadjuvant ICI Without Chemotherapy Demonstrates Potential Efficacy in Patients with Early-Stage... November 21, 2024 Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy July 13, 2020 How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... April 14, 2021 Load more HOT NEWS Her Massive Weight Loss Helped Her Feel A Lump In Her... 10 Things Diet Soda Does to Your Body If You Drink... Why is Colorectal Cancer Rising Rapidly among Young Adults? First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival...
